Search research articles
Contact Us
Filters
Showing results (101-110 of 170) with videos related to
Page
of 17
Sort By:
JAMA Network Open
|
August 1, 2023
Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial
Nicolas Sayegh, Umang Swami, Yeonjung Jo, et al.
Clinical Genitourinary Cancer
|
December 25, 2024
Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma
Nicolas Sayegh, Yeonjung Jo, Georges Gebrael, et al.
Cancers
|
June 19, 2024
Treatment Patterns and Outcomes by Age in Metastatic Urinary Tract Cancer: A Retrospective Tertiary Cancer Center Analysis
Nishita Tripathi, Georges Gebrael, Beverly Chigarira, et al.
Prostate Cancer and Prostatic Diseases
|
August 24, 2023
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors
Georges Gebrael, Nicolas Sayegh, Vinay Mathew Thomas, et al.
Prostate Cancer and Prostatic Diseases
|
July 17, 2023
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors
Georges Gebrael, Nicolas Sayegh, Vinay Mathew Thomas, et al.
Cancers
|
October 13, 2021
Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States
Umang Swami, Jennifer Anne Sinnott, Benjamin Haaland, et al.
Bladder Cancer (Amsterdam, Netherlands)
|
April 1, 2026
Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab
Georges Gebrael, Yeonjung Jo, Zeynep Irem Ozay, et al.
The Oncologist
|
August 23, 2021
Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results
Benjamin L Maughan, Adam Kessel, Taylor Ryan McFarland, et al.
Therapeutic Advances in Urology
|
November 11, 2024
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix
Patrick Campbell, Georges Gebrael, Arshit Narang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2025
Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma
Yousef Zakharia, Ryan J Reis, Matthew R Kroll, et al.
Page
of 17
Search research articles
Search
Showing results (101-110 of 170) with videos related to
Sort By:
Page
of 17
JAMA Network Open
|
August 1, 2023
Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial
Nicolas Sayegh, Umang Swami, Yeonjung Jo, et al.
Clinical Genitourinary Cancer
|
December 25, 2024
Real-world Effectiveness of Single-Agent Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma
Nicolas Sayegh, Yeonjung Jo, Georges Gebrael, et al.
Cancers
|
June 19, 2024
Treatment Patterns and Outcomes by Age in Metastatic Urinary Tract Cancer: A Retrospective Tertiary Cancer Center Analysis
Nishita Tripathi, Georges Gebrael, Beverly Chigarira, et al.
Prostate Cancer and Prostatic Diseases
|
August 24, 2023
Correction: Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors
Georges Gebrael, Nicolas Sayegh, Vinay Mathew Thomas, et al.
Prostate Cancer and Prostatic Diseases
|
July 17, 2023
Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors
Georges Gebrael, Nicolas Sayegh, Vinay Mathew Thomas, et al.
Cancers
|
October 13, 2021
Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States
Umang Swami, Jennifer Anne Sinnott, Benjamin Haaland, et al.
Bladder Cancer (Amsterdam, Netherlands)
|
April 1, 2026
Treatment patterns and outcomes with second-line therapies in patients with advanced urothelial carcinoma previously treated with first-line enfortumab vedotin with pembrolizumab
Georges Gebrael, Yeonjung Jo, Zeynep Irem Ozay, et al.
The Oncologist
|
August 23, 2021
Radium-223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results
Benjamin L Maughan, Adam Kessel, Taylor Ryan McFarland, et al.
Therapeutic Advances in Urology
|
November 11, 2024
Testosterone suppression and recovery in patients with advanced prostate cancer treated with intermittent androgen deprivation therapy with relugolix
Patrick Campbell, Georges Gebrael, Arshit Narang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 29, 2025
Phase I Clinical Trial of High Doses of Seleno-L-methionine in Combination with Axitinib in Patients with Previously Treated Metastatic Clear-cell Renal Cell Carcinoma
Yousef Zakharia, Ryan J Reis, Matthew R Kroll, et al.
Page
of 17